IRX-2 is a biologic product that contains multiple cytokines produced under pharmaceutical standards from phytohemagglutinin (PHA) stimulated mononuclear cells obtained from normal healthy donors. The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial low dose of cyclophosphamide and a 3-week course of indomethacin and zinc supplementation.